Recently, a novel CCDC6-ALK fusion was found in a 10 year old child with metastatic MTC that progressed to RET inhibitor selpercatinib, but rapidly responded when treatment was switched to ALK inhibitor alectinib [146]. This evidence concerns the gene ALK and medullary thyroid gland carcinoma.